Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414010 | PMC |
| http://dx.doi.org/10.3389/fncir.2022.977404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis.
Front Cell Neurosci
December 2024
Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.
Multiple sclerosis (MS), a debilitating autoimmune disorder targeting the central nervous system (CNS), is marked by relentless demyelination and inflammation. Clinically, it presents in three distinct forms: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). While disease-modifying therapies (DMTs) offer some relief to people with RRMS, treatment options for progressive MS (pMS) remain frustratingly inadequate.
View Article and Find Full Text PDFTelehealth in arts therapies for neurodevelopmental and neurological disorders: a scoping review.
Front Psychol
December 2024
Department of Health Psychology and Paedagogy, Rīga Stradiņš University, Riga, Latvia.
Background: Arts therapies, encompassing art therapy, music therapy, drama therapy, and dance movement therapy with the broader practice of expressive arts therapies, have demonstrated positive outcomes in the treatment of neurodevelopmental and neurological disorders (NNDs). Integrating arts therapies into telehealth has become increasingly important to improve accessibility for people with mobility impairments or those living in remote areas. This study aims to map the existing body of literature to provide an in-depth overview of telehealth in arts therapies for individuals with NNDs.
View Article and Find Full Text PDFEditorial: Radiomics and connectomics: applications to central nervous system diseases.
Front Neurol
December 2024
Jena University Hospital, Jena, Germany.
Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis.
Lancet Psychiatry
January 2025
Hampshire and Isle of Wight NHS Foundation Trust, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; Developmental EPI Evidence Synthesis, Prediction, Implementation Lab, Centre for Innovation in Mental Health-School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; New York University Child Study Center, Hassenfeld Children's Hospital at NYU Langone, New York, NY, USA; Department of Precision and Regenerative Medicine and Ionian Area, University of Studies of Bari Aldo Moro, Bari, Italy.
Background: The comparative benefits and harms of available interventions for ADHD in adults remain unclear. We aimed to address these important knowledge gaps.
Methods: In this systematic review and component network meta-analysis (NMA), we searched multiple databases for published and unpublished randomised controlled trials (RCTs) investigating pharmacological and non-pharmacological interventions for ADHD in adults from database inception to Sept 6, 2023.
Pharmacological management of gambling disorder: A systematic review and network meta-analysis.
Compr Psychiatry
December 2024
Department of Psychiatry, Faculty of Medicine, University of Southampton, UK and Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK.
Article Synopsis
- Clinical guidelines for medications treating gambling disorder are unclear, prompting a network meta-analysis to compare their efficacy and tolerability.
- The study reviewed 22 randomized controlled trials, ultimately analyzing 16 with nearly 1,000 participants, focusing on gambling symptom severity and quality of life as efficacy outcomes.
- Nalmefene showed the most promise in reducing gambling severity and improving quality of life, although it and naltrexone had higher dropout rates due to side effects, indicating lower tolerability compared to placebo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!